More on SRPT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $15.68 |
|
|||
| Open | $16.46 | ||||
| 52 Wk High | $63.73 | ||||
| 52 Wk Low | $8.00 | ||||
| Day High | $16.69 | ||||
| Day Low | $15.88 | ||||
| P/E | N/A | ||||
| EPS | $-5.69 | ||||
| Volume | 3,701,423 | ||||
- Form 8-K Sarepta Therapeutics, For: Jul 23
- Sarepta Therapeutics names Michael Severino as new CEO
- Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
- Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
- Sarepta Therapeutics (SRPT) PT Lowered to $20 at Piper Sandler
- Wolfe Research Upgrades Sarepta Therapeutics (SRPT) to Outperform
- H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
- FDA accepts Sarepta's applications to convert two DMD drugs to full approval
Entities mentioned with SRPT
- FDA | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
